Avinger, a manufacturer of multifunctional catheters, has received CE Mark approval for Pantheris, a lumectomy catheter designed to remove the blockage while avoiding the disruption of normal arterial wall structures. This lumivascular ...
The US Food and Drug Administration (FDA) has granted regulatory approval to Avinger's Ocelot | PIXL. Ocelot | PIXL, which is supported by the company's Lightbox console, enables physicians to navigate lesions with a choice between 135cm ...
Avinger, a manufacturer of multi-functional catheters, has raised $33m in Series D financing round. The finance was raised based on the completion of the company's Connect II global clinical trial for Ocelot catheter, which is integrated ...
Tags: Avinger, multi-functional catheters, peripheral artery diseases
Austin Heart, a provider of cardiac and vascular services, has started enrolling peripheral arterial disease (PAD) patients for Avinger's Connect II trial. The multi-center, non-randomized and prospective trial is designed to evaluate ...
Tags: Austin Heart, PAD patients, Connect II trial, peripheral arterial disease
Avinger has reported that it will present the CONNECT II clinical trial results at the Vascular Interventional Advances (VIVA) conference being held in Las Vegas, Nevada, US, between 9-12 October 2012. The prospective, multi-center, ...
Avinger has completed enrolling peripheral artery disease (PAD) patients in its CONNECT II clinical trial. The prospective, multi-center, non-randomized trial that evaluated 100 PAD patients with femoropopliteal CTO lesions was ...
Tags: clinical trial, peripheral artery disease, clinical technology, Avinger